| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
|
N Engl J Med
|
2006
|
18.25
|
|
2
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
|
N Engl J Med
|
2006
|
5.07
|
|
3
|
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.
|
Arch Intern Med
|
2008
|
3.68
|
|
4
|
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
|
Circulation
|
2003
|
3.38
|
|
5
|
Aspirin dose for the prevention of cardiovascular disease: a systematic review.
|
JAMA
|
2007
|
3.28
|
|
6
|
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
|
JAMA
|
2008
|
3.09
|
|
7
|
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.
|
Am J Cardiol
|
2005
|
3.05
|
|
8
|
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
|
JAMA
|
2004
|
2.89
|
|
9
|
Variability in platelet responsiveness to clopidogrel among 544 individuals.
|
J Am Coll Cardiol
|
2005
|
2.59
|
|
10
|
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
|
J Am Coll Cardiol
|
2007
|
2.56
|
|
11
|
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
|
Am Heart J
|
2004
|
2.42
|
|
12
|
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
|
Eur Heart J
|
2007
|
2.31
|
|
13
|
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
|
Circulation
|
2010
|
2.27
|
|
14
|
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
|
Circulation
|
2008
|
2.05
|
|
15
|
Platelet function monitoring in patients with coronary artery disease.
|
J Am Coll Cardiol
|
2007
|
1.97
|
|
16
|
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.
|
Circulation
|
2009
|
1.77
|
|
17
|
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
|
Circulation
|
2007
|
1.67
|
|
18
|
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
|
J Am Coll Cardiol
|
2007
|
1.66
|
|
19
|
Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.
|
J Am Coll Cardiol
|
2008
|
1.62
|
|
20
|
Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization.
|
J Invasive Cardiol
|
2006
|
1.61
|
|
21
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
|
JACC Cardiovasc Interv
|
2009
|
1.56
|
|
22
|
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
|
Eur Heart J
|
2009
|
1.49
|
|
23
|
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
|
Am Heart J
|
2011
|
1.47
|
|
24
|
Early coronary revascularization diminishes the risk of ischemic stroke with acute myocardial infarction.
|
Stroke
|
2006
|
1.44
|
|
25
|
Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass.
|
J Thromb Thrombolysis
|
2012
|
1.41
|
|
26
|
Variable response to antiplatelet therapy: what does it mean to clinicians?
|
Cleve Clin J Med
|
2007
|
1.40
|
|
27
|
Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study).
|
Am J Cardiol
|
2002
|
1.37
|
|
28
|
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
|
Circulation
|
2006
|
1.35
|
|
29
|
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.
|
JACC Cardiovasc Interv
|
2011
|
1.26
|
|
30
|
Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested.
|
Circulation
|
2003
|
1.14
|
|
31
|
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
|
Circulation
|
2008
|
1.14
|
|
32
|
G-protein-coupled receptors as signaling targets for antiplatelet therapy.
|
Arterioscler Thromb Vasc Biol
|
2008
|
1.10
|
|
33
|
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
|
Am Heart J
|
2008
|
1.10
|
|
34
|
The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.
|
J Am Coll Cardiol
|
2006
|
1.09
|
|
35
|
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.
|
J Am Coll Cardiol
|
2009
|
1.07
|
|
36
|
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
|
Am Heart J
|
2008
|
1.07
|
|
37
|
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
|
Eur Heart J
|
2012
|
1.02
|
|
38
|
Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.
|
J Clin Pharmacol
|
2009
|
0.99
|
|
39
|
Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry.
|
JACC Cardiovasc Interv
|
2010
|
0.97
|
|
40
|
Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.
|
Am J Cardiol
|
2006
|
0.97
|
|
41
|
Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
|
J Am Heart Assoc
|
2013
|
0.97
|
|
42
|
Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.
|
Arch Intern Med
|
2004
|
0.95
|
|
43
|
Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention.
|
Int J Cardiol
|
2010
|
0.95
|
|
44
|
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.
|
J Am Coll Cardiol
|
2010
|
0.95
|
|
45
|
Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
|
Am Heart J
|
2011
|
0.90
|
|
46
|
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
|
Circulation
|
2004
|
0.90
|
|
47
|
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
|
Am Heart J
|
2008
|
0.90
|
|
48
|
Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
|
J Invasive Cardiol
|
2007
|
0.89
|
|
49
|
Early detection of heart failure with varying prediction windows by structured and unstructured data in electronic health records.
|
Conf Proc IEEE Eng Med Biol Soc
|
2015
|
0.88
|
|
50
|
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
JACC Cardiovasc Interv
|
2008
|
0.88
|
|
51
|
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.
|
J Am Coll Cardiol
|
2004
|
0.87
|
|
52
|
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.
|
Coron Artery Dis
|
2009
|
0.86
|
|
53
|
Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial.
|
Arch Cardiovasc Dis
|
2009
|
0.85
|
|
54
|
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
|
Am J Cardiol
|
2009
|
0.85
|
|
55
|
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
|
Eur Heart J
|
2008
|
0.85
|
|
56
|
Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils.
|
Arterioscler Thromb Vasc Biol
|
2007
|
0.84
|
|
57
|
Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.
|
Circulation
|
2010
|
0.84
|
|
58
|
Oral fluids that detect cardiovascular disease biomarkers.
|
Oral Surg Oral Med Oral Pathol Oral Radiol
|
2012
|
0.83
|
|
59
|
Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
|
Circ Cardiovasc Interv
|
2012
|
0.83
|
|
60
|
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.
|
Am Heart J
|
2009
|
0.83
|
|
61
|
How Consumers and Physicians View New Medical Technology: Comparative Survey.
|
J Med Internet Res
|
2015
|
0.83
|
|
62
|
Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study.
|
Med Care
|
2016
|
0.83
|
|
63
|
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
|
Am Heart J
|
2010
|
0.82
|
|
64
|
Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
|
Arch Intern Med
|
2007
|
0.82
|
|
65
|
Heparin-induced thrombocytopenia and cardiovascular diseases.
|
Am Heart J
|
2006
|
0.82
|
|
66
|
Resistance to antiplatelet resistance is it justified?
|
J Am Coll Cardiol
|
2005
|
0.82
|
|
67
|
Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model.
|
Oral Surg Oral Med Oral Pathol Oral Radiol
|
2012
|
0.81
|
|
68
|
Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
|
Catheter Cardiovasc Interv
|
2009
|
0.81
|
|
69
|
The Influence of Wireless Self-Monitoring Program on the Relationship Between Patient Activation and Health Behaviors, Medication Adherence, and Blood Pressure Levels in Hypertensive Patients: A Substudy of a Randomized Controlled Trial.
|
J Med Internet Res
|
2016
|
0.81
|
|
70
|
Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?
|
Pharmacol Ther
|
2010
|
0.80
|
|
71
|
A brief review of the past and future of platelet P2Y12 antagonist.
|
Coron Artery Dis
|
2012
|
0.80
|
|
72
|
Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development.
|
Platelets
|
2008
|
0.79
|
|
73
|
Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
|
Am Heart J
|
2003
|
0.79
|
|
74
|
Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention.
|
Am J Cardiol
|
2004
|
0.79
|
|
75
|
Usefulness of the response to sublingual nitroglycerin as a predictor of ischemic chest pain in the emergency department.
|
Am J Cardiol
|
2002
|
0.79
|
|
76
|
Ticagrelor: the first novel reversible P2Y(12) inhibitor.
|
Expert Opin Pharmacother
|
2012
|
0.79
|
|
77
|
Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy.
|
J Thromb Thrombolysis
|
2011
|
0.79
|
|
78
|
Point-of-care determination of baseline platelet function as a predictor of clinical outcomes in patients who present to the emergency department with chest pain.
|
J Thromb Thrombolysis
|
2004
|
0.78
|
|
79
|
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
|
Am Heart J
|
2002
|
0.78
|
|
80
|
Incidence and prevention of ischemic stroke following myocardial infarction: review of current literature.
|
Cerebrovasc Dis
|
2006
|
0.78
|
|
81
|
Platelet activation and its patient-specific consequences.
|
Thromb Res
|
2007
|
0.78
|
|
82
|
Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses.
|
Circ Cardiovasc Interv
|
2012
|
0.78
|
|
83
|
The use of anti-inflammatory analgesics in the patient with cardiovascular disease: what a pain.
|
J Am Coll Cardiol
|
2005
|
0.77
|
|
84
|
High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial.
|
Heart
|
2011
|
0.77
|
|
85
|
Can health insurance improve employee health outcome and reduce cost? An evaluation of Geisinger's employee health and wellness program.
|
J Occup Environ Med
|
2013
|
0.77
|
|
86
|
Development of a multi-institutional cohort to facilitate cardiovascular disease biomarker validation using existing biorepository samples linked to electronic health records.
|
Clin Cardiol
|
2013
|
0.77
|
|
87
|
Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
|
Am Heart J
|
2007
|
0.77
|
|
88
|
Impact of genetic polymorphisms on clinical response to antithrombotics.
|
Pharmgenomics Pers Med
|
2010
|
0.77
|
|
89
|
Clopidogrel: how good is it and how does it work?
|
Curr Cardiol Rep
|
2004
|
0.76
|
|
90
|
Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction.
|
Curr Cardiol Rep
|
2002
|
0.76
|
|
91
|
Aspirin following PCI: too much of a good thing?
|
Eur Heart J
|
2009
|
0.76
|
|
92
|
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
|
Am Heart J
|
2005
|
0.76
|
|
93
|
Risk reduction with long-term clopidogrel following percutaneous coronary intervention.
|
Eur Heart J
|
2004
|
0.76
|
|
94
|
Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects.
|
J Thromb Thrombolysis
|
2014
|
0.76
|
|
95
|
Vulnerable plaque intervention: State of the art.
|
Catheter Cardiovasc Interv
|
2008
|
0.75
|
|
96
|
Monitoring of platelet function in the setting of glycoprotein IIb/IIIa inhibitor therapy.
|
J Interv Cardiol
|
2002
|
0.75
|
|
97
|
Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.
|
CMAJ
|
2006
|
0.75
|
|
98
|
Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
|
Thromb Res
|
2012
|
0.75
|
|
99
|
Clopidogrel for percutaneous coronary revascularization: time for more pretreatment, retreatment, or both?
|
JAMA
|
2005
|
0.75
|
|
100
|
Antiplatelet effect of aspirin in patients with cerebrovascular disease.
|
Stroke
|
2004
|
0.75
|
|
101
|
Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough.
|
JAMA
|
2006
|
0.75
|
|
102
|
Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
|
J Am Coll Cardiol
|
2003
|
0.75
|
|
103
|
Atrial fibrillation in the setting of acute myocardial infarction--irregularly irregular treatment.
|
Am Heart J
|
2008
|
0.75
|
|
104
|
The illusion of "optimal" platelet inhibition.
|
JACC Cardiovasc Interv
|
2012
|
0.75
|
|
105
|
Clopidogrel-statin interaction: a mountain or a mole hill?
|
Am Heart J
|
2006
|
0.75
|
|
106
|
Percutaneous coronary interventions in patients with renal insufficiency: a high-risk, under-studied cohort.
|
Am Heart J
|
2003
|
0.75
|
|
107
|
Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study.
|
Med Care
|
2017
|
0.75
|
|
108
|
Medication burden in patients with acute coronary syndromes.
|
Am J Manag Care
|
2017
|
0.75
|
|
109
|
Oral antiplatelet therapy for percutaneous coronary revascularization.
|
Catheter Cardiovasc Interv
|
2007
|
0.75
|
|
110
|
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
|
Expert Rev Cardiovasc Ther
|
2003
|
0.75
|
|
111
|
Bivalirudin, thrombin and platelets: clinical implications and future directions.
|
J Invasive Cardiol
|
2003
|
0.75
|
|
112
|
Cangrelor in percutaneous coronary intervention.
|
Expert Rev Clin Pharmacol
|
2009
|
0.75
|
|
113
|
Platelet-mediated thrombosis and drug-eluting stents.
|
Circ Cardiovasc Interv
|
2011
|
0.75
|
|
114
|
Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study.
|
Am Heart J
|
2005
|
0.75
|